pipette
ESEspañol

The p53-p21-Cyclin D2 regulatory axis drives metabolic reprogramming and a distinct senescent macrophage senotype during aging and MASLD.

G. Torres, I. A. Salladay-Perez, C. Y. Deng, I. Avila, Y. Delgado, G. Tong, J. Munoz-Estrada, L. Estrada, A. Dhingra, W. R. Armstrong, A. Singh, I. Cooper, E. Enriquez, P. Kaushal, J. Ni, K. Chowdhury, C. Pan, L. Stiles, C. Beninca, S. T. Hui, A. Krall, H. Christofk, A. J. Lusis, T. E. O'Sullivan, J. G. Meyer, R. Singh, V. A. Tornini, O. S. Shirihai, M. Bouhaddou, A. J. Covarrubias

PreprintReal-world use

In the authors' words

Aging drives chronic disease in part through senescent cells, including macrophages, which fuel inflammation. Senescent macrophages are functionally heterogeneous: canonical p16-high macrophages promote tumorigenesis or, in other contexts, disease tolerance, whereas we previously identified a distinct p21-high, p16-low senotype that drives metabolic dysfunction-associated steatotic liver disease (MASLD). The molecular basis of this senotype has remained undefined. Using genetic and multi-omic approaches, we show that a p53-p21-dependent program actively represses p16 and is required for senescent macrophage viability. We identify Cyclin D2 as a non-canonical downstream effector that redistributes from the nucleus to mitochondria and lipid droplets, where it partners with MIC60 to drive metabolic reprogramming and modulates AKT1-mTORC1 signaling that sustains the SASP. Cyclin D2-p21 double-positive macrophages accumulate with aging and MASLD in mice and in human liver cirrhosis, and can be selectively depleted by senolytic treatment. Together, these findings define a druggable p53-p21-Cyclin D2 axis that specifies macrophage senotype.

Main resultThe abstract does not state a limitation.

Appeared: Tuesday, September 29. bioRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.09.22.753597